Moleculin Biotech, Inc. (MBRX)

Moleculin Biotech's stock price has experienced significant volatility, decreasing by 90.18% over the last 12 months. Key events impacting the stock in the past six months include positive clinical trial results for WP1066 and Annamycin, trial progress and milestones for the MIRACLE Phase 3 AML trial, financial and regulatory updates such as the exercise of warrants and regaining compliance with Nasdaq's minimum bid price rule, and analyst ratings from HC Wainwright & Co. Despite some positive updates, the stock has shown a tendency for good news to coincide with selling pressure.

As a clinical-stage pharmaceutical company, Moleculin Biotech does not currently generate revenue from product sales, so there is no direct demand seasonality for its products and services. However, there is a noted monthly seasonality in the stock's performance, with July historically showing the highest probability of a positive return and May the lowest, relating to investor behavior and market trends rather than product demand.

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing novel drug candidates for hard-to-treat cancers and viruses. The company's core mission is to advance a pipeline of proprietary molecules through clinical trials to address significant unmet medical needs, particularly drug resistance and toxicity issues in oncology. Its product portfolio includes Annamycin, a next-generation anthracycline; the WP1066 Portfolio, which are immune/transcription modulators; and the WP1122 Portfolio, which contains antimetabolites/glycolysis inhibitors.

Moleculin Biotech's clinical trials, particularly the pivotal Phase 2B/3 MIRACLE trial for Annamycin, have a global reach, spanning nine countries, including the US and various European nations, with over 46 sites selected and approximately 20 sites contracted.

Moleculin Biotech's brand reputation has been shaped by its ongoing clinical advancements and efforts to address critical medical needs. Positive clinical trial results, Annamycin's safety profile, Orphan Drug and Fast Track Designations, and analyst endorsements have positively impacted its reputation. However, there have been instances where good news coincided with selling pressure on the stock, suggesting that market reaction to positive developments can be mixed.

Moleculin Biotech has a significant portion of its stock owned by institutional investors, with 15.52% of the stock held by institutions as of late 2025. Major institutional owners include Vanguard Group Inc., Geode Capital Management, LLC, and Blackrock, Inc. Individual investors hold a substantial portion of the company's stock, with the largest individual shareholder being Co-Founder and Founding Scientist Waldemar Priebe, who owns approximately 12.04% of the company.